MNK - Mallinckrodt And VTS-270 In Niemann-Pick Disease Type C: The Competition
The Clinical Trial
Mallinckrodt (MNK) is a small-cap ($245M) commercial-stage global specialty pharmaceutical company developing innovative therapeutics for diseases including autoimmune and rare diseases. Through several acquisitions and in-house research, MNK has developed a diverse pipeline presently in different phases of clinical development.
VTS-270 (2-hydroxypropyl-?-cyclodextrin) is an investigative drug candidate acquired from Sucampo Pharmaceuticals. In Q4/2018, MNK reported that the Phase 2b/3 study of VTS-270 in Niemann-Pick Type C (NPC.) did not achieve the primary outcome. MNK elaborates:
In our recently completed registration trial, the product did not show a statistically